Buy me a coffee · $1
×

Support us with a small donation 💝

Every coffee keeps the site running. Thank you!

GLP-1 Receptor Agonist Expansion Reshapes Pharmaceutical R&D Budgets

 ·  1 min read

Pharmaceutical executives are reallocating clinical research budgets to capture market share in oral peptide and small-molecule metabolic treatments.

Pipeline Restructuring and Clinical Trial Capacity
R&D spending on traditional cardiovascular and metabolic compounds fell 9% as capital gravitated toward phase-three trials for once-daily oral GLP-1 candidates showing superior patient adherence rates.